Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus TRAVASOL 5 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus TRAVASOL 5 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
AMINOSYN 8.5% (PH6) vs TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% (pH 6) provides a mixture of essential and nonessential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral or enteral nutrition.
Travasol 5.5% with electrolytes provides a source of amino acids and electrolytes for parenteral nutrition, supporting protein synthesis and maintaining metabolic balance.
1-1.5 g amino acids/kg/day intravenously, typically 500 mL of a 8.5% solution (42.5 g amino acids) infused over 8-24 hours.
Intravenous: 500 mL to 2 L per day, infused at a rate of 20-40 mL/kg/day (0.5-1.5 g amino acids/kg/day) based on metabolic needs and tolerance.
None Documented
None Documented
Not applicable as a fixed value; elimination half-life of individual amino acids varies (minutes to hours) and is dependent on metabolic demand and renal function.
Not applicable; components are endogenous and rapidly cleared. Amino acids have short half-lives (e.g., alanine ~15 min; leucine ~30 min) and are continuously metabolized. Terminal elimination of water and electrolytes follows body fluid kinetics.
Primarily renal; elimination depends on metabolic utilization. Unused amino acids are deaminated and excreted as urea in urine (over 90%). Fecal elimination is negligible.
Primarily renal; 90-100% eliminated as free amino acids, electrolytes, and water. Metabolized nitrogen is excreted as urea. Biliary/fecal: negligible (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution